Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76dd75c94c-nbtfq Total loading time: 0 Render date: 2024-04-30T08:34:49.182Z Has data issue: false hasContentIssue false

Chapter 25 - Human Immunodeficiency Virus

from Section III - Care of the Elderly by Organ System

Published online by Cambridge University Press:  30 June 2022

By
David Alain Wohl  and
Christina Prather
Edited by
Jan Busby-Whitehead ,
Samuel C. Durso ,
Christine Arenson ,
Rebecca Elon ,
Mary H. Palmer  and
William Reichel
Jan Busby-Whitehead
Affiliation:
University of North Carolina, Chapel Hill
Samuel C. Durso
Affiliation:
The Johns Hopkins University, Maryland
Christine Arenson
Affiliation:
Thomas Jefferson University, Philadelphia
Rebecca Elon
Affiliation:
The Johns Hopkins University School of Medicine
Mary H. Palmer
Affiliation:
University of North Carolina, Chapel Hill
William Reichel
Affiliation:
Georgetown University Medical Center
Get access

Summary

In the USA, the majority of people living with HIV infection are older than 50 years of age. As these individuals get older, they face many of the challenges common to the aging experience but often earlier and more often. Cardiovascular, renal, bone, and liver disease, as well as mental health and substance use disorders, are more prevalent among people living with HIV than the general population. While factors related to HIV and its therapies can contribute to the risk of comorbid conditions associated with aging, data suggests more traditional factors are the main drivers. As such, clinicians caring for those living with HIV must be attuned to these risk factors, especially those for which interventions can prevent or delay their onset. All clinicians should recognize the importance of screening for HIV infection, starting with a good sexual and substance use history. Pre-Exposure Prophylaxis (PrEP) is a safe and effective biomedical intervention that can prevent HIV acquisition and should not be avoided or neglected as an option for those over 50, a population that makes up 15% of new diagnoses of HIV.

Keywords

HIVagingfrailtycomorbiditiesPrEP
Type
Chapter
Information
Reichel's Care of the Elderly
Clinical Aspects of Aging
 , pp. 310 - 323
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centers for Disease Control and Prevention. HIV Surveillance Report, 2018 (Updated); vol. 31. www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2020. Accessed on 05/22/2021.Google Scholar
Centers for Disease Control and Prevention. HIV and older Americans. www.cdc.gov/hiv/group/age/olderamericans/index.html. Accessed on 05/22/2021.Google Scholar
Pathai, S, Bajillan, H, Landay, AL, High, KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014 (Jul.); 69(7):833–842.Google Scholar
Guaraldi, G, Orlando, G, Zona, S, Menozzi, M, Carli, F, Garlassi, E, Berti, A, Rossi, E, Roverato, A, Palella, F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011 (Dec.); 53(11):1120–1126.Google Scholar
Deeks, SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 62(2011):141–155.CrossRefGoogle ScholarPubMed
Schouten, J, Wit, FW, Stolte, IG, Kootstra, NA, van der Valk, M, Geerlings, SE, Prins, M, Reiss, P; AGEhIV Cohort Study Group. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: The AGEhIV cohort study. Clin Infect Dis. 2014 (Dec. 15); 59(12):1787–1797.Google Scholar
Falutz, J, Brañas, F, Erlandson, KM. Frailty: The current challenge for aging people with HIV. Curr Opin HIV AIDS. 2021 (May 1); 16(3):133–140.Google Scholar
Geretti, AM, Stockdale, AJ, Kelly, SH, Cevik, M, Collins, S, Waters, L, Villa, G, Docherty, A, Harrison, EM, Turtle, L, Openshaw, PJM, Baillie, JK, Sabin, CA, Semple, MG. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): A prospective observational study. Clin Infect Dis. 2020 (Oct. 23):ciaa1605.CrossRefGoogle Scholar
Althoff, KN, Smit, M, Reiss, P, Justice, AC. HIV and ageing: Improving quantity and quality of life. Curr Opin HIV AIDS. 2016 (Sep.); 11(5):527–536.Google Scholar
Marcus, JL, Leyden, WA, Alexeeff, SE, Anderson, AN, Hechter, RC, Hu, H, Lam, JO, Towner, WJ, Yuan, Q, Horberg, MA, Silverberg, MJ. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000–2016. JAMA Netw Open. 2020 (Jun. 1); 3(6):e207954.Google Scholar
Gueler, A, Moser, A, Calmy, A, et al; Swiss HIV Cohort Study, Swiss National Cohort. Life expectancy in HIV-positive persons in Switzerland: Matched comparison with general population. AIDS. 2017; 31(3):427–436.Google Scholar
Glaude-Hosch, JA, Smith, ML, Heckman, TG, Miles, TP, Olubajo, BA, Ory, MG. Sexual behaviors, healthcare interactions, and HIV-related perceptions among adults age 60 years and older: An investigation by race/ethnicity. Curr HIV Res. 2015; 13(5):359–368.CrossRefGoogle ScholarPubMed
Onen, NF, Shacham, E, Stamm, KE, Overton, ET. Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection. AIDS Care. 2010; 22(6):711–717.CrossRefGoogle ScholarPubMed
Althoff, KN, Gebo, KA, Gange, SJ, et al. CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? AIDS Res Ther. 2010; 7:45.Google Scholar
Ask, Screen, Intervene: Effective Prevention in HIV Care. https://aidsetc.org/resource/ask-screen-intervene-effective-prevention-hiv-care. Accessed on 05/21/2021.Google Scholar
Centers for Disease Control and Prevention. A guide to taking a sexual history. www.cdc.gov/std/treatment/sexualhistory.pdf. Accessed on 05/21/2021.Google Scholar
Bradley, KA, Lapham, GT, Lee, AK. Screening for drug use in primary care: Practical implications of the new USPSTF recommendation. JAMA Intern Med. 2020; 180(8):1050–1051.Google Scholar
Peters, PJ, Pontones, P, Hoover, KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016; 375:229–239.Google Scholar
Hodder, SL, Feinberg, J, Strathdee, SA, Shoptaw, S, Altice, FL, Ortenzio, L, Beyrer, C. The opioid crisis and HIV in the USA: Deadly synergies. Lancet. 2021 (Mar. 20); 397(10279):1139–1150.Google Scholar
Branson, BM, Handsfield, HH, Lampe, MA, Janssen, RS, Taylor, AW, Lyss, SB, Clark, JE; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 (Sep. 22); 55(RR-14):1–17.Google Scholar
Final Recommendation Statement. Human Immunodeficiency Virus (HIV) Infection: Screening. June 2019. www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening. Accessed on 05/21/2021.Google Scholar
Lindau, ST, Schumm, LP, Laumann, EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007; 357(8):762–774.Google Scholar
Centers for Disease Control and Prevention (CDC). HIV testing. www.cdc.gov/hiv/guidelines/testing.html. Accessed on 05/21/2021.Google Scholar
Triant, VA, Lee, H, Hadigan, C, Grinspoon, SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007 (Jul.); 92(7):2506–2512.Google Scholar
Paisible, AL, et al. Human immunodeficiency virus infection, cardiovascular risk factor profile and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015; 68:209–216.Google Scholar
Gustafson, DR, Shi, Q, Thurn, M, et al. Frailty and constellations of factors in aging HIV-infected and uninfected women: The women’s interagency HIV Study. J Frailty Aging. 2016; 5:43–48.Google Scholar
Althoff, KN, Gebo, KA, Moore, RD, et al; North American AIDS Cohort Collaboration on Research and Design. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: A collaboration of cohort studies. Lancet HIV. 2019 (Feb.); 6(2):e93–e104.CrossRefGoogle Scholar
Johnsen, S, Dolan, SE, Fitch, KV, Kanter, JR, Hemphill, LC, Connelly, JM, Lees, RS, Lee, H, Grinspoon, S. Carotid intimal medial thickness in human immunodeficiency virus-infected women: Effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab. 2006 (Dec.); 91(12):4916–4924.Google Scholar
Post, WS, Budoff, M, Kingsley, L, Palella, FJ Jr, Witt, MD, Li, X, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014 (Apr. 1); 160(7):458–467.Google Scholar
Pramukti, I, Lindayani, L, Chen, YC, et al. Bone fracture among people living with HIV: A systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS One. 2020; 15:e0233501Google Scholar
Cohen, RA, Seider, TR, Navia, B. HIV effects on age-associated neurocognitive dysfunction: Premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther. 2015; 7:37.Google Scholar
Desquilbet, L, Jacobson, LP, Fried, LP, Phair, JP, Jamieson, BD, Holloway, M, Margolick, JB; Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007 (Nov.); 62(11):1279–1286.CrossRefGoogle ScholarPubMed
Hunt, PW, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003 (May 15); 187(10):1534–4331.Google Scholar
Sandler, NG, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011 (Mar. 15); 203(6):780–790. 32.Google Scholar
Brenchley, JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 (Dec.); 12(12):1365–1371.Google Scholar
Margolick, JB, Bream, JH, Nilles, TL, et al. Relationship between T-cell responses to CMV, markers of inflammation, and frailty in HIV-uninfected and HIV-infected men in the multicenter AIDS Cohort Study. J Infect Dis. 2018; 218:249–258.Google Scholar
Althoff, KN, Smit, M, Reiss, P, Justice, AC. HIV and ageing: Improving quantity and quality of life. Curr Opin HIV AIDS. 2016; 11(5):527–536.CrossRefGoogle ScholarPubMed
Friis-Møller, N, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2015; 23(2):214–223.CrossRefGoogle ScholarPubMed
Wohl, DA, Yazdanpanah, Y, Baumgarten, A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019; 6(6):E355–E363.CrossRefGoogle ScholarPubMed
Venter, WDF, Moorhouse, M, Sokhela, S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019; 381(9):803–815.Google Scholar
Kasaie, P, Stewart, C, Humes, E, et al. Multimorbidity in people with HIV using ART in the US: Projections to 2030. CROI 2021, Conference on Retroviruses and Opportunistic Infections, March 6–10, 2021. Abstract 102.Google Scholar
Klein, DB, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015; 60:1278–1280.Google Scholar
Feinstein, MJ, Hsue, PY, Benjamin, LA, Bloomfield, GS, Currier, JS, Freiberg, MS, Grinspoon, SK, Levin, J, Longenecker, CT, Post, WS. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association. Circulation. 2019 (Jul. 9); 140(2):e98–e124.Google Scholar
Triant, VA, Regan, S, Lee, H, Sax, PE, Meigs, JB, Grinspoon, SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010; 55:615–619.Google Scholar
Lichtenstein, KA, Armon, C, Buchacz, K, Chmiel, JS, Buckner, K, Tedaldi, EM, Wood, K, Holmberg, SD, Brooks, JT; HIV Outpatient Study (HOPS) Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010; 51:435–447.Google Scholar
Silverberg, MJ, Leyden, WA, Xu, L, Horberg, MA, Chao, CR, Towner, WJ, Hurley, LB, Quesenberry, CP, Klein, DB. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014; 65:160–166.Google Scholar
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr, WM, Lundgren, J, Neaton, JD, Gordin, F, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355:2283–2296.Google Scholar
Lundgren, JD, Babiker, AG, Gordin, F, et al.; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373:795–807.Google Scholar
Hsue, PY, Scherzer, R, Hunt, PW, Schnell, A, Bolger, AF, Kalapus, SC, Maka, K, Martin, JN, Ganz, P, Deeks, SG. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc. 2012; 1:jah3–e000422.CrossRefGoogle ScholarPubMed
Nordell, AD, McKenna, M, Borges, ÁH, Duprez, D, Neuhaus, J, Neaton, JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014; 3:e000844.Google Scholar
DAD Study Group, Friis-Møller, N, Reiss, P, Sabin, CA, Weber, R, Monforte, Ad, El-Sadr, W, Thiébaut, R, De Wit, S, Kirk, O, Fontas, E, Law, MG, Phillips, A, Lundgren, JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356:1723–1735.Google ScholarPubMed
D:A:D Study Group, Sabin, CA, Worm, SW, Weber, R, Reiss, P, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet. 2008; 371:1417–1426.Google Scholar
Monforte, Ad, Reiss, P, Ryom, L, El-Sadr, W, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS. 2013; 27:407–415.CrossRefGoogle ScholarPubMed
Rasmussen, LD, Helleberg, M, May, MT, Afzal, S, Kronborg, G, Larsen, CS, Pedersen, C, Gerstoft, J, Nordestgaard, BG, Obel, N. Myocardial infarction among Danish HIV-infected individuals: Population-attributable fractions associated with smoking. Clin Infect Dis. 2015; 60:1415–1423.Google Scholar
Myerson, M, Malvestutto, C, Aberg, JA. Management of lipid disorders in patients living with HIV. J Clin Pharmacol. 2015; 55:957–974.Google Scholar
Lucas, GM, Ross, MJ, Stock, PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(9):e96–138. www.ncbi.nlm.nih.gov/pubmed/25234519.Google Scholar
Schwartz, EJ, Szczech, LA, Ross, MJ, Klotman, ME, Winston, JA, Klotman, PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol. 2005; 16(8):2412–2420.CrossRefGoogle ScholarPubMed
Hamzah, L, Jose, S, Booth, J, Hegazi, A, Rayment, M, Bailey, A, et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. J Infect. 2017; 74(5):492–500.Google Scholar
Wyatt, CM. Antiretroviral therapy and the kidney. Top Antivir Med. 2014 (Jun.–Jul.); 22(3):655–658.Google ScholarPubMed
Aloy, B, Tazi, I, Bagnis, CI, Gauthier, M, Janus, N, Launay-Vacher, V, et al. Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys? AIDS Rev. 2016; 18(4):184–192.Google Scholar
Hileman, CO, Eckard, AR, McComsey, GA. Bone loss in HIV: A contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015 (Dec.); 22(6):446–451.Google Scholar
McCommey, GA, Tebas, P, Shane, E, Yin, MT, Overton, ET, Huang, JS, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis. 2010 (Oct. 15); 51(8):937–946.Google Scholar
Shiau, S, Broun, EC, Arpadi, SM, Yin, MT. Incident fractures in HIV-infected individuals: A systematic review and meta-analysis. AIDS. 2013; 27:1949–1957.Google Scholar
Aukrust, P, Haug, CJ, Ueland, T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999; 84:145–150.Google Scholar
Brown, TT, McComsey, GA, King, MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009; 51:554–561.Google Scholar
Aberg, JA, Gallant, JE, Ghanem, KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 58:1–10.Google Scholar
European AIDS Clinical Society. European AIDS Clinical Society Guidelines Version 7.1. 2014 (Nov.); www.eacsociety.org/files/guidelines-7.1-english.pdf.Google Scholar
McComsey, GA, Tebas, P, Shane, E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis. 2010; 51:937–946.Google Scholar
Brown, TT, Hoy, J, Borderi, M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015; 60:1242–1251.Google Scholar
Cosman, F, de Beur, SJ, LeBoff, MS, Lewiecki, EM, Tanner, B, Randall, S, Lindsay, R; National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014 (Oct.); 25(10):2359–2381. doi: 10.1007/s00198-014-2794-2. Erratum in: Osteoporos Int. 2015 (Jul.); 26(7):2045–2047.Google Scholar
Do, AN, et al. Excess burden of depression among HIV-infected persons receiving medical care in the United States: Data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS ONE. 2014; 9:e92842.Google Scholar
Zuniga, JA, Yoo-Jeong, M, Dai, T, Guo, Y, Waldrop-Valverde, D. The role of depression in retention in care for persons living with HIV. AIDS Patient Care STDS. 2016; 30:34–38.Google Scholar
Pence, BW, Miller, WC, Gaynes, BN, Eron, JJ Jr. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 (Feb. 1); 44(2):159–166.Google Scholar
Milanini, B, Catella, S, Perkovich, B, et al. Psychiatric symptom burden in older people living with HIV with and without cognitive impairment: The UCSF HIV over 60 cohort study. AIDS Care. 2017; 29(9):1178–1185. www.ncbi.nlm.nih.gov/pubmed/28127989.CrossRefGoogle ScholarPubMed
Grov, C, Golub, SA, Parsons, JT, Brennan, M, Karpiak, SE. Loneliness and HIV-related stigma explain depression among older HIV-positive adults. AIDS Care. 2010; 22(5):630–639. www.ncbi.nlm.nih.gov/pubmed/20401765.Google Scholar
Crane, HM, Crane, PK, Tufano, JT, et al. HIV provider documentation and actions following patient reports of at-risk behaviors and conditions when identified by a web-based point-of-care assessment. AIDS Behav. 2017 (Nov.); 21(11):3111–3121.Google Scholar
Nanni, MG, Caruso, R, Mitchell, AJ, et al. Depression in HIV infected patients: A review. Curr Psychiatry Rep. 2015; 17:530.Google Scholar
Heaton, RK, Franklin, DR, Ellis, RJ, McCutchan, JA, Letendre, SL, Leblanc, S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol. 2011 (Feb.); 17(1):3–16.Google Scholar
Ances, BM, Ellis, RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol. 2007 (Feb.); 27(1):86–92.Google Scholar
McArthur, JC, Haughey, N, Gartner, S, Conant, K, Pardo, C, Nath, A, et al. Human immunodeficiency virus-associated dementia: An evolving disease. J Neurovirol. 2003 (Apr.); 9(2):205–221.Google Scholar
Work Group for HIV and Aging Consensus Project. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: Treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc. 2012 (May); 60(5):974–979.Google Scholar
Power, C, Selnes, OA, Grim, JA, McArthur, JC. HIV Dementia Scale: A rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 (Mar. 1); 8(3):273–278.Google Scholar
Valcour, V, Paul, R, Chiao, S, Wendelken, LA, Miller, B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011 (Oct.); 53(8):836–842.Google Scholar
Garg, S, Brooks, J, Luo, Q, Skarbinski, J. Prevalence of and Factors Associated with Hepatitis C Virus (HCV) Testing and Infection Among HIV-infected Adults Receiving Medical Care in the United States. Philadelphia, PA: Infectious Disease Society of America (IDSA), 2014.Google Scholar
Yaphe, S, Bozinoff, N, Kyle, R, Shivkumar, S, Pai, NP, Klein, M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: A systematic review. Sex Transm Infect. 2012; 88:558–564.Google Scholar
Agarwal, K, Brunetto, M, Seto, WK, et al.; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 (Apr.); 68(4):672–681.CrossRefGoogle ScholarPubMed
Crane, HM, McCaul, ME, Chander, G, et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. AIDS Behav. 2017; 21(7):1914–1925.Google Scholar
Lim, JK, Tate, JP, Fultz, SL, et al. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis. 2014; 58(10):1449–1458.Google Scholar
Lake, JE, Overton, T, Naggie, S, Sulkowski, M, Loomba, R, Kleiner, DE, Price, JC, Chew, KW, Chung, RT, Corey, KE. Expert panel review on non-alcoholic fatty liver disease in persons with HIV. Clin Gastroenterol Hepatol. 2020 (Oct. 16):S1542–3565(20)31431–2.Google Scholar
Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149:367–378.Google Scholar
Schrack, JA, et al. Accelerated longitudinal gait speed decline in HIV-infected older men. J Acquir Immune Defic Syndr. 2015; 70:370–376.Google Scholar
Brennan, DJ, Emlet, CA, Eady, A. HIV, sexual health, and psychosocial issues among older adults living with HIV in North America. Ageing International. 2011; 36(3):313–333.Google Scholar
Althoff, KN. The silver tsunami: Projecting multimorbidity, polypharmacy, and healthcare costs for those aging with HIV in the US. Grantome. Project No. 5R01AG053100-04. https://grantome.com/grant/NIH/R01-AG053100-04.Google Scholar
Silverberg, MJ, Leyden, W, Horberg, MA, DeLorenze, GN, Klein, D, Quesenberry, CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007 (Apr. 9); 167(7):684–691.Google Scholar
Onen, NF, Shacham, E, Stamm, KE, Overton, ET. Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection. AIDS Care. 2010; 22(6):711–717.Google Scholar
Golub, SA, Tomassilli, JC, Pantalone, DW, Brennan, M, Karpiak, SE, Parsons, JT. Prevalence and correlates of sexual behavior and risk management among HIV-positive adults over 50. Sex Transm Dis. 2010; 37(10):615–620.Google Scholar
Brooks, JT, Buchacz, K, Gebo, KA, Mermin, J. HIV infection and older Americans: The public health perspective. Am J Public Health. 2012; 102(8):1516–1526.Google Scholar
US Public Health Service. Preexpoure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update Clinical Practice Guideline. www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Accessed on 05/21/2021.Google Scholar
Grant, RM, Lama, JR, Anderson, PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587–2599.CrossRefGoogle ScholarPubMed
Baeten, JM, Donnell, D, Ndase, P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399–410.Google Scholar
Thigpen, MC, Kebaabetswe, PM, Paxton, LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423–434.Google Scholar
Choopanya, K, Martin, M, Suntharasamai, P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083–2090.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×